ReviewChest2025
The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease.
Review in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Diagnostic, prognostic, and therapeutic challenges in patients with hypersensitivity pneumonitis.ERJ open research · 2026Review
- Immunopeptidome profiling in pulmonary fibrosis: linking antigenicity to cytotoxic immunity and therapeutic targeting.Signal transduction and targeted therapy · 2026Article
- The transcriptome of CD14The European respiratory journal · 2026Article
- Progressive pulmonary fibrosis: the importance of identification and intervention.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications.International journal of molecular sciences · 2025Review
- Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study.BMC pulmonary medicine · 2025Article
- Precision Medicine Advances in Chronic Lung Diseases.International journal of molecular sciences · 2025Article
- Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis.Scientific reports · 2025Observational
- Peripheral and pulmonary telomere lengths in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases.BMC pulmonary medicine · 2025Article
- Aging-associated interleukin-11 drives the molecular mechanism and targeted therapy of idiopathic pulmonary fibrosis.European journal of medical research · 2025Review
- ITGAV, a specific biomarker associated with the pathogenesis of idiopathic pulmonary fibrosis.Scientific reports · 2025Article
- Macrophage subtypes and pathways in autoimmune interstitial lung diseases: potential therapeutic targets.Frontiers in immunology · 2025Article
- Global, regional, and national burden of interstitial lung diseases and pulmonary sarcoidosis from 2000 to 2021: a systematic analysis of incidence, mortality, and disability-adjusted life years.Frontiers in public health · 2025Article
- Advances in clinical research on interstitial lung disease.Frontiers in medicine · 2025Review
- Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: aFrontiers in pharmacology · 2025Article
- Article
- Protective Effects of Qingre Sanjie Jiaonang on Pulmonary Fibrosis: A Pilot Study.Journal of inflammation research · 2025Article
- Exercise improves pulmonary fibrosis and neurological symptoms via S100A12 inhibition.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
topic importanceInterstitial lung diseases (ILDs) represent a broad group of heterogeneous parenchymal lung diseases. Some ILDs progress, causing architectural distortion and pulmonary fibrosis, and thus are called fibrotic ILDs. Recent studies have shown a beneficial effect of antifibrotic therapy in fibrotic ILDs other than idiopathic pulmonary fibrosis (IPF) that manifest progressive pulmonary fibrosis (PPF). However, it remains challenging to predict which patients with fibrotic ILDs will demonstrate PPF. Precision medicine approaches could identify patients at risk for progression and guide treatment in patients with IPF or PPF. REVIEW
findingsMultiple biomarkers able to highlight disease susceptibility risk, to provide an accurate diagnosis, and to prognosticate or assess treatment response have been identified. Advances in precision medicine led to the identification of endotypes that could discriminate patients with different fibrotic ILDs or patients with different disease courses. Importantly, recent studies have shown that particular compounds were efficacious only in particular endotypes. The aforementioned findings are promising. However, implementation in clinical practice remains an unmet need. SUMMARY: Substantial progress has been observed in the context of precision medicine approaches in fibrotic ILDs in recent years. Nonetheless, infrastructure, financial, regulatory, and ethical challenges remain before precision medicine can be implemented in clinical practice. Overcoming such barriers and moving from a one-size-fits-all approach to patient-centered care could improve patient quality of life and survival substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.